Amplicore's Team

Tina Chen, MA, CCRC

Director of Clinical Affairs

Pharmaceutical Project Manager

Pharmaceutical Project Manager

C. James Lin, PhD

Founder

President & Chief Executive Officer

Francis J. Tinney Ph.D., J.D.

Senior Patent Counsel

Tyler Vandivort, PhD

Senior Manager of Regulatory Affairs

James Hamby, PhD

Senior Vice President

of Business Development

Tina Chen, MA, CCRC

Director of Clinical Affairs

Administrative Coordinator​

Amalia Tollas

Felix Chang, JD

General Counsel

VP of Finance & Administration

Stacey Gruber, PhD

Pharmaceutical Project Manager

Advisory Board

Michael Archdeacon, MD

Chair, Amplicore Advisory Board 

Dr. Archdeacon is the Peter J. Stern Professor and Chairman of the Department of Orthopaedic Surgery at University of Cincinnati College of Medicine. As a prominent leader in the orthopaedic society, Dr. Archdeacon will help chair the Advisory Board for Amplicore. He will also provide his clinical expertise and guidance to facilitate the translation of the Amplicore technologies to the orthopaedic clinic.

Advisor

Andrew A. Freiberg, MD

Dr. Freiberg is an attending surgeon at Newton Wellesley Hospital in Boston as part of Mass General Brigham, where he specializes in the treatment of osteoarthritis. He is the former Chief Medical Officer of Zimmer Biomet and previously worked for twenty years as Chief of the Hip and Knee Unit at Massachusetts General Hospital. He was also the Interim Department Chair of the Department of Orthopedic Surgery at MGH and a Professor of Orthopedic Surgery at Harvard Medical School. Dr. Freiberg brings to the Board a wealth of experience in primary and revision arthroplasty, arthroscopic treatments, and business management and commercialization of orthopaedic new products.

Vijay Baragi, PhD

Advisor

Dr. Baragi is the Chief Scientific Officer at the Center for Neurologic Studies in Dearborn, Michigan. He is an expert in the development of intra-articular cartilage repair and regeneration strategies for the treatment of osteoarthritis (OA) – a key target of Amplicore’s technologies. He was among the leadership for drug discovery and development in osteoarthritis and inflammation therapeutic areas through his long career at Park-Davis/Pfizer and Alantos Pharmaceuticals (acquired by Amgen in 2007). His wide-ranging experience spans drug discovery, preclinical and clinical development, and regulation, as well as senior executive experience in the pharmaceutical industry. Dr. Baragi brings to the Board expertise and guidance on the crucial pre-clinical and clinical phases.

Amplicore, Inc.

5412 Courseview Drive, Suite 125

Mason, OH 45204

(513) 204-0084

©2019 by Amplicore